2.99
-0.50 (-14.33%)
| Previous Close | 3.49 |
| Open | 3.28 |
| Volume | 763,732 |
| Avg. Volume (3M) | 365,139 |
| Market Cap | 3,861,785 |
| Price / Book | 3.12 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2025 |
| Diluted EPS (TTM) | -41.44 |
| Total Debt/Equity (MRQ) | 2.13% |
| Current Ratio (MRQ) | 1.90 |
| Operating Cash Flow (TTM) | -13.43 M |
| Levered Free Cash Flow (TTM) | -7.63 M |
| Return on Assets (TTM) | -122.21% |
| Return on Equity (TTM) | -259.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Indaptus Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.33 |
|
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 36.87% |
| % Held by Institutions | 13.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Pine Valley Investments Ltd Liability Co | 31 Dec 2024 | 1,568 |
| Bangor Savings Bank | 30 Jun 2025 | 0 |
| Investment House Llc | 30 Jun 2025 | 0 |
| Strategy Asset Managers Llc | 30 Jun 2025 | 0 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Sep 2025 | Announcement | Indaptus Therapeutics Provides Clinical Update |
| 02 Sep 2025 | Announcement | Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference |
| 13 Aug 2025 | Announcement | Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |